Giselle Sholler

This trial is testing if adding a new drug called naxitamab to the standard first round of chemotherapy can better control a serious childhood cancer called high-risk neuroblastoma. It will involve about 93 children and young adults up to age 21 who are newly diagnosed. The goal …

This study is testing whether a drug called DFMO, taken as a pill twice daily for two years, can help prevent the aggressive brain cancer medulloblastoma from coming back. It is for children and young adults (up to age 21) who have a high-risk form of the disease or whose cancer …

This study is testing a two-drug combination (DFMO and etoposide) for children and young adults whose neuroblastoma has come back (relapsed) or hasn't responded to standard treatments (refractory). The goal is to see if this treatment can help patients live longer without their c…

This study is testing a new combination of two drugs for children and young adults whose high-risk neuroblastoma has returned or not responded to standard treatments. It combines an experimental pill called tipifarnib with an approved IV drug, naxitamab. The main goals are to see…

This trial provides expanded access to an experimental drug called DFMO for children and young adults (ages 0-30) with rare, relapsed cancers like neuroblastoma and medulloblastoma. The goal is to see if DFMO can help control these aggressive cancers after standard treatments hav…

This study is testing a personalized treatment approach for children and young adults with high-risk neuroblastoma, an aggressive childhood cancer. It first uses genetic testing to select targeted drugs alongside standard chemotherapy, then tests whether adding an experimental dr…

This study is testing whether a pill called DFMO can prevent neuroblastoma, a serious childhood cancer, from coming back in patients who are currently in remission. It will involve 441 children and young adults considered high-risk, who will take the pill daily for two years. The…

This study aims to collect tumor samples and health information from children and young adults with cancer, as well as survivors and healthy volunteers. Researchers will store these samples and data in a central registry to study how genetic changes in tumors relate to patient ou…